Anixa Biosciences, Inc. (ANIX) financial statements (2021 and earlier)

Company profile

Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250
SAN JOSE, CA 95118
State of Incorp. DE
Fiscal Year End October 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

1/31/2021
Q1
10/31/2020
Q4
7/31/2020
Q3
4/30/2020
Q2
1/31/2020
Q1
10/31/2019
Q4
7/31/2019
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments14996666
Cash and cash equivalents12663334
Short-term investments2333322
Receivables 000000
Other undisclosed current assets1000000
Total current assets:15996667
Noncurrent Assets
Operating lease, right-of-use asset00000  
Property, plant and equipment   0000
Intangible assets, net (including goodwill)     (2)(2)
Intangible assets, net (excluding goodwill)     (2)(2)
Other undisclosed noncurrent assets 00  22
Total noncurrent assets:0000000
TOTAL ASSETS:15996667
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1111111
Accounts payable1000011
Accrued liabilities1111111
Debt    0  
Other undisclosed current liabilities0000   
Total current liabilities:2111111
Noncurrent Liabilities
Long-term debt and lease obligation  000  
Operating lease, liability  000  
Other undisclosed noncurrent liabilities  (0)(0)   
Total noncurrent liabilities:  000  
Total liabilities:2111111
Stockholders' equity
Stockholders' equity attributable to parent14995556
Common stock0000000
Additional paid in capital207200198192190187185
Accumulated deficit(194)(192)(190)(187)(184)(182)(180)
Stockholders' equity attributable to noncontrolling interest(1)(0)(0)(0)(0)(0)(0)
Total stockholders' equity:13885555
TOTAL LIABILITIES AND EQUITY:15996667

Income statement (P&L) ($ in millions)

1/31/2021
Q1
10/31/2020
Q4
7/31/2020
Q3
4/30/2020
Q2
1/31/2020
Q1
10/31/2019
Q4
7/31/2019
Q3
Revenues1      
Cost of revenue(1)(0)(1)(1)(1)0 
Gross profit:(1)(0)(1)(1)(1)0 
Operating expenses(2)(2)(1)(1)(1)(3)(2)
Other undisclosed operating income      0
Operating loss:(2)(2)(2)(3)(3)(2)(2)
Nonoperating income (expense)  (0)0000
Investment income, nonoperating   0000
Other nonoperating expense  (0)    
Interest and debt expense  (0)    
Other undisclosed income from continuing operations before equity method investments, income taxes 0     
Loss before gain (loss) on sale of properties:(2)(2)(3)(3)(3)(2)(2)
Other undisclosed net income (loss)0(0)0    
Net loss:(2)(2)(3)(3)(3)(2)(2)
Net income attributable to noncontrolling interest0000000
Net loss available to common stockholders, diluted:(2)(2)(3)(3)(3)(2)(2)

Comprehensive Income ($ in millions)

1/31/2021
Q1
10/31/2020
Q4
7/31/2020
Q3
4/30/2020
Q2
1/31/2020
Q1
10/31/2019
Q4
7/31/2019
Q3
Net loss:(2)(2)(3)(3)(3)(2)(2)
Comprehensive loss:(2)(2)(3)(3)(3)(2)(2)
Comprehensive income, net of tax, attributable to noncontrolling interest0000000
Comprehensive loss, net of tax, attributable to parent:(2)(2)(3)(3)(3)(2)(2)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: